Macquarie Group’s ClearPoint Neuro CLPT Stock Holding History

Macquarie Group’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,125	Closed	-$6.06K	–	1707
2024 Q2	$6.06K	Buy	+1,125	New	+$6.51K	﹤0.01%	1694

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CWM

Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return

Macquarie Group's CLPT Position: Q3 2024 in Review

Macquarie Group sold out of ClearPoint Neuro (CLPT) in Q3 2024, closing a stake of 1,125 shares — an estimated $6.06K sold.

Macquarie Group first reported a position in CLPT in Q2 2024 and held it in 1 quarter. The position peaked at $6.06K in Q2 2024. 78 funds tracked by Wall St. Rank hold CLPT as of Q3 2024.

Macquarie Group reported no remaining ClearPoint Neuro position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 1,125 ClearPoint Neuro shares in Q3 2024, an estimated $6.06K.
Macquarie Group first reported a position in ClearPoint Neuro in Q2 2024 and held it in 1 quarter.
Macquarie Group's ClearPoint Neuro position peaked at $6.06K in Q2 2024.
78 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.